Clovis Nzinga-Lusivika

Paris, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Viral clearance and escape during therapy of COVID-19 outpatients: A prospective cohort study.

Viral clearance and escape during therapy of COVID-19 outpatients: A prospective cohort study.

Journal: iScience
Published: June 02, 2025

Revisiting the link between COVID-19 incidence and infection fatality rate during the first pandemic wave.

Revisiting the link between COVID-19 incidence and infection fatality rate during the first pandemic wave.

Journal: Scientific reports
Published: October 21, 2024

Value of non-invasive test dynamics in guiding HCC surveillance decisions after HCV cure in patients with cirrhosis.

Value of non-invasive test dynamics in guiding HCC surveillance decisions after HCV cure in patients with cirrhosis.

Journal: Journal of hepatology
Published: July 02, 2024

Spike Protein Genetic Evolution in Patients at High Risk of Severe Coronavirus Disease 2019 Treated by Monoclonal Antibodies.

Spike Protein Genetic Evolution in Patients at High Risk of Severe Coronavirus Disease 2019 Treated by Monoclonal Antibodies.

Journal: The Journal of infectious diseases
Published: July 26, 2023

Impaired health-related quality of life in the HCV cure era: who is concerned? (ANRS CO22 HEPATHER French cohort).

Impaired health-related quality of life in the HCV cure era: who is concerned? (ANRS CO22 HEPATHER French cohort).

Journal: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
Published: July 21, 2023

Antiviral activities of sotrovimab against BQ.1.1 and XBB.1.5 in sera of treated patients.

Antiviral activities of sotrovimab against BQ.1.1 and XBB.1.5 in sera of treated patients.

Journal: medRxiv : the preprint server for health sciences
Published: July 03, 2023

Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients.

Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients.

Journal: Med (New York, N.Y.)
Published: June 09, 2023

Dynamic personalized prediction of the individual liver-related risk after sustained viral response in HCV patients.

Dynamic personalized prediction of the individual liver-related risk after sustained viral response in HCV patients.

Journal: Journal of viral hepatitis
Published: January 09, 2023

Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir.

Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir.

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
Published: October 12, 2022

Performance of algorithms for identifying patients with chronic hepatitis B or C infection in the french health insurance claims databases using the ANRS CO22 HEPATHER cohort.

Performance of algorithms for identifying patients with chronic hepatitis B or C infection in the french health insurance claims databases using the ANRS CO22 HEPATHER cohort.

Journal: Journal of viral hepatitis
Published: August 29, 2022

Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2.

Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2.

Journal: The Journal of infection
Published: June 28, 2022

Impact of direct-acting antiviral treatment for hepatitis C on cardiovascular diseases and extrahepatic cancers.

Impact of direct-acting antiviral treatment for hepatitis C on cardiovascular diseases and extrahepatic cancers.

Journal: Pharmacoepidemiology and drug safety
Published: April 21, 2022
Showing 1-12 of 21

Last Updated: 09/26/2026